Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Tenchusatsu who wrote (1331785)	12/3/2021 12:21:05 PM
From: Broken_Clock	Read Replies (1) \| Respond to of 1573149

ncbi.nlm.nih.gov Vaccine. 2021 Apr 15; 39(16): 2190–2200. 5. Concluding remarksmRNA is a rising star in the field of biopharmaceuticals. The interest in this new type of vaccine derives from the flexibility, safety, and precision that these vaccines present when compared to conventional approaches. The growing number of clinical trials for cancer therapies and infectious diseases demonstrates an increased interest from the industry to release these types of vaccines to the market. mRNA vaccines are precise, safe and flexible, which can be easily manufactured on a large scale for clinical grade applications. These vaccines can be an answer to quickly respond to epidemic outbreaks in terms of manufacturing. However, to achieve this status, the development of sustainable and cost-effective manufacturing processes must be addressed. Although the IVT reaction of mRNA is safer and quicker than most of the established vaccines production, it relies on the use of expensive and limited materials. Downstream processing of the vaccine is still poorly established, and it is dependent on methods that lack scalability and cost-effectiveness. Moving the process to continuous manufacturing can overcome these bottlenecks. We propose a microfluidics approach with the compartmentalisation of enzymatic reactions coupled with in situ product removal (ISPR) and substrate feed and product recovery (SDPR) modules and the use of multimodal chromatography to replace the use of multiple chromatographic steps ( Fig. 5). The use of new production methods that allow the reuse and recirculation of compounds integrated with high-throughput purification and well-defined analytical methods in a continuous manufacturing process can be the answer for a sustainable, flexible and cost-effective vaccine manufacture that can allow an on-demand response.

To: Tenchusatsu who wrote (1331785)	12/3/2021 1:09:22 PM
From: Winfastorlose	2 Recommendations Recommended By isopatch Mick Mørmøny Read Replies (1) \| Respond to of 1573149

The point is that the article maintains a huge expenditure of 400 million British pounds and hiring 350 new technicians to bring online extra capacity and that the expansion will not be complete until 2023 or 2024. Martin Meeson, chief executive of Fujifilm Diosynth Biotechnologies, said: “There has never been a more important time to invest in biopharmaceuticals and £400m, the largest investment in British biopharmaceutical manufacturing for decades, signals our intent … to help solve public health demands, and deliver the medicines and vaccines of tomorrow. Now. If you know about the FDA approval of Cominarty (The Pfizer jab) then you will also know that there is only one BioNTech plant in Germany that has been approved to produce the approved version so far and according to the approval letter, all vaxes must come from that plant and that plant alone if they are to be sold in the USA. Once you get a feel for the logistics of pharmaceutical production, his statements make sense. Never in history have any vaccines been produced inside of one year to the tune of multiple billions. We also now that so far, over 460 million doses of Covid jabs have been administered in the USA alone and we are only 11 months into this.